Stifel analysts maintained their Buy rating on Iovance Biotherapeutics (NASDAQ:IOVA), currently trading at $5.24, with a steady price target of $21.00. According to InvestingPro data, analyst targets ...
Stifel analysts increased their price target for Ecolab Inc . (NYSE:ECL) shares to $307.00, up from the previous $285.00, while reiterating a Buy rating on the stock. The company, currently valued at ...
Stifel analyst Paul Matteis lowered the firm’s price target on Biogen (BIIB) to $144 from $175 and keeps a Hold rating on the shares. The ...
Stifel Financial is a top pick for long-term growth with solid Q424 results, a 10% dividend hike & solid wealth management ...
Stifel raised the firm’s price target on Confluent (CFLT) to $40 from $37 and keeps a Buy rating on the shares following what the firm calls “a ...
GATX Corporation (NYSE: GATX) announced the cancellation of its presentation and webcast at the Stifel 2025 Transportation & ...
MoneyLion operates a “content-as-a-service platform” called mFeed, and Stifel Discover is expected to deliver personalized ...
Over the past five years, Stifel has hired 450 advisors, with a cumulative trailing 12-month production of more than $350 million, according to CFO Marischen. That has driven the wealth division’s ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
(美国商业资讯)-- 全球领先的全数字化航空航天零部件制造商Sintavia, LLC今日宣布，已从Stifel North Atlantic AM-Forward Fund（以下简称“基金”）获得1000万美元的次级债务投资。这笔投资是最近推出的SBIC基金的首笔投资，其资金将用于为现有设备贷款再 ...
周三，Stifel分析师维持对Palo Alto ...
在其他近期新闻中，卡夫亨氏受到多位分析师评级调整。Jefferies分析师Rob Dickerson将卡夫亨氏目标价从34美元下调至30美元，同时维持"持有"评级。此次调整是基于观察到公司在美国市场，特别是第四季度出现显著的销量下滑和市场份额损失。
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback